NDAORALSOLUTION
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
QUIOFIC (folic acid) by Teva is clinical pharmacology folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. First approved in 2026.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIOFIC is an oral folic acid solution approved by FDA on January 26, 2026, indicated for treating megaloblastic and macrocytic anemias caused by folic acid deficiency. It works by converting to tetrahydrofolic acid, a cofactor essential for DNA synthesis and nucleoprotein production, thereby restoring normal erythropoiesis and converting megaloblastic bone marrow to normoblastic marrow.
Launch
As a newly launched oral solution from Teva, this product offers entry-level commercial opportunity in a moderate competitive environment with potential for field team expansion during initial market penetration phase.
Mechanism of Action
CLINICAL PHARMACOLOGY Folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. In man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as…
Worked on QUIOFIC at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.